New‐Onset Headache in Patients With Autoimmune Encephalitis Is Associated With anti‐NMDA‐Receptor Antibodies. Issue 6 (31st May 2016)

• Record Type: Journal Article
• Authors: Schankin, Christoph J.; Kästele, Fabian; Gerdes, Lisa Ann; Winkler, Tobias; Csanadi, Endy; Högen, Tobias; Pellkofer, Hannah; Paulus, Walter; Kümpfel, Tania; Straube, Andreas
• Is Part Of: Headache. Volume 56:Issue 6(2016)
• Page Start: 995
• Page End: 1003
• Publication Date: 2016-05-31
• Subjects: limbic encephalitis -- autoimmune encephalitis -- anti‐NMDA‐receptor antibodies -- headache -- migraine -- secondary headache; Headache -- Periodicals; Headache -- Periodicals; 616.8491
• DOI: 10.1111/head.12853
• Languages: English
• ISSNs: 0017-8748

Abstract

Abstract : Objective: We tested the hypotheses (i) that autoimmune encephalitis is associated with new‐onset headache, and (ii) that the occurrence of headache is associated with the presence of anti‐N‐methyl‐D‐aspartate (NMDA)‐receptor antibodies. Background: Autoimmune encephalitis presents with cognitive dysfunction as well as neuro‐psychiatric symptoms. Its pathophysiology might involve antibody‐mediated dysfunction of the glutamatergic system as indicated by the presence of anti‐NMDA‐receptor antibodies in some patients. Methods: In this cross‐sectional study, patients with autoimmune encephalitis were assessed with a standardized interview for previous headache and headache associated with autoimmune encephalitis. Headache was classified according to the International Classification of Headache Disorders, second edition. Clinical and paraclinical findings were correlated with the occurrence of headache. Results: Of 40 patients with autoimmune encephalitis, 19 did not have a history of headache. Of those, nine suffered from encephalitis‐associated headache. Seven of these nine had anti‐NMDA‐receptor antibodies in contrast to only two among the remaining 10 patients without new‐onset headache ( P = .023, odds ratio: 14, 95% confidence interval: 1.5; 127). In most patients headache occurred in attacks on more than 15 days/month, was severe, and of short duration (less than 4 hours). International Headache Society criteria for migraine were met in three patients. Conclusions: New‐onset headache is a relevant symptom in patients with autoimmune encephalitis who have no history of previous headache, especially in the subgroup with anti‐NMDA‐receptor antibodies. This indicates a thorough investigation for secondary headaches including anti‐NMDA‐R antibodies for patients with new‐onset headache and neuropsychiatric findings. Glutamatergic dysfunction might be important for the generation of head pain but may only occasionally be sufficient to trigger migraine‐like attacks in nonmigraineurs.